Value frameworks aren't at an ideal point in their development, yet, but it is important to keep in mind that different frameworks represent different perspectives, said Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.
Value frameworks aren't at an ideal point in their development, yet, but it is important to keep in mind that different frameworks represent different perspectives, said Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.
Transcript
Finding common ground among stakeholders when using value frameworks has been difficult. Do you think we're any closer to an ideal or well-balanced value framework?
I think we are closer, we aren’t at an ideal, but the important thing that’s happened with value frameworks is that the organizations that are involved in providing care and financing care have been more explicit about their preferences. So the value frameworks that you see from organizations like ASCO {American Society of Clinical Oncology] and NCCN [National Comprehensive Cancer Network] represent the perspectives of those organizations. And just clarifying that is an important step towards finding harmonization.
What changes would you like to see within the existing frameworks in oncology, such as NCCN, Institute for Clinical and Econommic Review, and ASCO?
The initial thing I would like to see them do is be more transparent about what they’re accounting for in terms of costs and outcomes and also to understand the perspective that they’re taking when they make judgments about those particular aspects of the value frameworks. Those of us in cost-effectiveness generally favor the quality-adjusted life-year [QALY] and a more complete accounting of costs than most of the existing value frameworks that aren’t based on cost per QALY, and I think we need more explicit understanding of where those frameworks are coming from before we can move forward.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More